National Institute of Standards and Technology (NIST)’s Post

We are excited to share our paper titled "Five multivariate Duchenne muscular dystrophy progression models bridging six‑minute walk distance and MRI relaxometry of leg muscles," published in the Journal of Pharmacokinetics and Pharmacodynamics. We developed five multivariate models by leveraging extensive data collected from the ImagingNMD study. The models will guide drug developers on using MRI-T2 imaging biomarkers most efficiently using the widely used functional endpoint. This work was funded by The National Institutes of Health and University of Florida, Clinical & Translational Science Institute (CTSI). See it here: https://lnkd.in/ee7sa7xn #modeling #simulation #midd #imaging #biomarker #dmd #raredisease

𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟰. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗶𝘇𝗲, 𝗦𝗵𝗮𝗿𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dZbdg5H8 The preclinical imaging market, valued at USD 2.8 billion in 2023, is projected to grow at a CAGR of 5%, reaching USD 4.7 billion by 2034. This field of medical imaging focuses on studying biological processes and diseases in small animal models, such as mice and rats, before human trials. Utilizing techniques like MRI, PET, CT, and optical imaging, researchers can visualize anatomical features, molecular interactions, and physiological activities at cellular and molecular levels. These non-invasive imaging methods are crucial for tracking disease progression, evaluating treatment efficacy, and understanding disease mechanisms. Preclinical imaging plays a vital role in drug development, enabling researchers to assess new treatments, understand their pharmacokinetics and pharmacodynamics, and make informed decisions before advancing to human trials, thus bridging the gap between basic research and practical medical applications. *𝗕𝘆 𝗣𝗿𝗼𝗱𝘂𝗰𝘁: Optical Imaging, PET, SPECT, Optical Imaging Reagents, Contrast Agents, Nuclear Imaging Reagents *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Oncology, Neurology, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Bruker, PerkinElmer, Siemens Healthineers, GE HealthCare, MR SOLUTIONS, Aspect Imaging, Mediso Medical Imaging Systems, MILabs, TriFoil Imaging, Agilent Technologies, FUJIFILM Holdings Corporation, Thermo Fisher Scientific, Miltenyi Biotec, Perceptive Instruments #PreclinicalImaging #MedicalImaging #AnimalModels #MRIImaging #PETImaging #CTImaging #OpticalImaging #DrugDevelopment #DiseaseProgression #TreatmentEfficacy #MolecularImaging #CellularImaging #Pharmacokinetics #Pharmacodynamics #NonInvasiveImaging #BiomedicalResearch #ImagingTechniques #SmallAnimalImaging #PreclinicalStudies #TranslationalResearch

As Jensen Huang (Nvidia CEO) recently said, if you are #excited about making a difference at scale, the intersection of #engineering and #biomedicine is the place to be! Established in April 2019, UC San Diego HUMANOID: Center of Excellence in Human Organoid Research was strategically placed as one of the 4 four pillars of transdisciplinary research within the UC San Diego Institute for Network Medicine (iNetMed). We celebrate that decision today, because HUMANOID is exactly where it needed to be to #make-a-difference at #scale, through its #LowCost solutions, efforts at #modeling and #benchmarking #invariant phenotypes (that withstand inter- and intra-patient #heterogeneity), with a focus on #rigor and #reproducibility. #organoids; #deeplearning; #precisionmedicine; #drugdiscovery; #biomarker.

Deep Learning on #organoids (#PDO) #risks 'garbage-in-garbage-out'. A 5-point strategy (👇read more) implemented at UC San Diego HUMANOID: Center of Excellence in Human Organoid Research #derisks this process: 1) A deep #biobank that is #representative of #disease and #healthy population; 2) Engage in #prospective biobanking (#learned behavior of #PDO should be related back to patient #outcome!); 3) Respect #epigenetics (e.g., iPS models of a gut, have no knowledge of the environment being modeled) and reduce #artifacts (when it comes to additives, less is more); 4) #Benchmark PDOs against a mathematically defined, omics-derived #precise and #invariant aspect of the diseased tissue, and these invariant #features are of the highest value for #SupervisedLearning; 5) Sift #information guided by #physicianscientists and SMEs in the disease area to know what is clinically #important and #actionable. Katherine Johnson, the remarkable NASA mathematician, once wisely stated, “In math, you're either right or you're wrong.”.... "Math is the same. If I gave you that answer last year, it's the same now". CELLphenomics GmbH; Molecular Devices; HUB Organoids; Curie.Bio; Biopico Systems INC; Emulate, Inc. Organovo Holdings, Inc.Vyant Bio; Hesperos Inc. Cherry Biotech Encapsulate; Tempus AI; Parallel Bio

Happy to read in The Straits Times this morning how Made-In-Singapore 🇸🇬 medical devices 🩺 is contributing to the growing industry, which is estimates to hit US$225 billion (S$304 billion) by 2030 in Asia alone. From the article, Singapore produced : 💉one in 10 contact lenses used globally 💉one in five cardiac-related global implants such as surgical structural heart valves, pacemakers and stents. 💉half the mass spectrometry systems used worldwide to test for a range of things such as drugs or food contamination and 90% of gene chips that allow scientists to evaluate and store large amounts of genetic data. #MadeInSingapore #QualityToTrust #Medtech #MedicalDevice https://lnkd.in/g4SCER64

One in 10 contact lenses used globally comes from Singapore, as does one in five cardiac-related implants such as surgical structural heart valves, pacemakers and stents. The Republic also produces half the mass spectrometry systems used worldwide to test for a range of things such as drugs or food contamination, and 90 per cent of gene chips that allow scientists to evaluate and store large amounts of genetic data. Made-in-Singapore medical devices are not the only ones punching above their weight in this growing market that the Economic Development Board (EDB) estimates will hit US$225 billion (S$304 billion) by 2030 in Asia alone.

Voxcan, part of the ERBC GROUP, specializes in non-invasive high-resolution imaging for non-clinical drug development. We offer advanced preclinical biodistribution studies using in vivo fluorescence imaging. ➡️ Our techniques enable real-time observation of labelled compounds' biodistribution with optimized NIR fluorochromes in both naïve and disease models. Combining bioluminescence with fluorescence imaging, we provide insights into compound colocalization with pathological processes over time. #3Rs #biodistribution #drugdevelopment #NAM #bioluminescence #fluorescenceImaging

𝐋𝐢𝐯𝐞 𝐂𝐞𝐥𝐥 𝐈𝐦𝐚𝐠𝐢𝐧𝐠: 𝐂𝐚𝐩𝐭𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐂𝐞𝐥𝐥𝐮𝐥𝐚𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 👉 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬: https://lnkd.in/gFxa-dDe 𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐥𝐢𝐯𝐞 𝐜𝐞𝐥𝐥 𝐢𝐦𝐚𝐠𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $2.7 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $4.3 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 10.2% 𝐟𝐫𝐨𝐦 2023 𝐭𝐨 2028 The live cell imaging market in 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region. Additionally, #NorthAmerica faces a significant burden of chronic diseases, including cancer, cardiovascular diseases, and #neurologicaldisorders. The increasing prevalence of chronic diseases in the region drives the demand for live cell imaging techniques for both research and clinical applications. The market in the #AsiaPacific region has experienced significant growth over the past few years. This growth can be attributed to several factors such as increasing investment in healthcare infrastructure and research & development (R&D) activities. Governments and private entities are allocating substantial funds and launching various research programs to enhance healthcare facilities and promote scientific advancements, including live cell imaging technologies. These investments are driving the adoption of live cell imaging techniques across various applications and research fields. 👉 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: Danaher Corporation, ZEISS Group, Nikon, Olympus Corporation, PerkinElmer, Sartorius, Agilent Technologies, Thermo Fisher Scientific, Etaluma, Inc., CytoSMART Technologies, NanoEnTek, Inc., GE HealthCare, Bruker, Becton, Dickinson and Company, Merck KGaA, Darmstadt, Germany, Bio-Rad Laboratories, Blue-Ray Biotech. Corp., CYTENA, Nanolive SA, abberior, Phase Holographic Imaging, Cytoskeleton, Inc., Corning Incorporated, KEYENCE CORPORATION, Aligned #LiveCellImaging #CellBiology #ImagingTechnology #Microscopy #BiomedicalResearch #CellResearch #BioImaging #CellImaging #ResearchInnovation #LifeSciences #Biotech #CellScience #AdvancedMicroscopy #BiotechInnovation #ScientificResearch

🔬 Shift in #AI-Driven #DrugDiscovery: From #CellPainting to Brightfield #Imaging https://lnkd.in/dBrDjvT3 Just read a fascinating analysis about how Recursion, a pioneer in AI-driven drug discovery, quietly shifted from cell painting back to traditional brightfield imaging in 2023. This seemingly technical decision carries profound implications for the entire biotech industry. ❗ Why this matters: ▶️ Cell painting, once heralded as a revolutionary #ImagingTechnique for drug discovery, appears to offer #NoSignificantAdvantages over basic #BrightfieldImaging when coupled with modern ML models. This challenges a decade of industry assumptions. ▶️ The shift to brightfield imaging isn't just about cost savings - it enables #LiveCellImaging and temporal analysis, potentially unlocking new insights about drug-cell interactions that were impossible with fixed cell painting methods. ▶️ #DeepLearning models can now extract the same information from simple brightfield images that previously required complex staining protocols. It's a perfect example of the "bitter lesson" in ML - sometimes simpler is better. 🔮 The future is dynamic: ▶️ Live cell imaging opens up entirely new possibilities for understanding #DrugCell interactions in real-time ▶️ Second-by-second #TemporalAnalysis could reveal critical mechanisms that static imaging misses ▶️ The ability to observe cellular responses over extended periods could transform our understanding of #DrugEfficacy ⚙️ Key technical requirements: ▶️ Success in this new paradigm demands robust #HighThroughputScreening systems ▶️ Advanced #imaging capabilities are crucial for capturing subtle cellular dynamics ▶️ Systems must handle #massive data throughput for temporal analysis at scale 💡 The implications are significant: ▶️ Companies heavily #invested in cell painting infrastructure may need to reevaluate their approach ▶️ The focus might shift from #static snapshots to #dynamic cell behavior analysis ▶️ Reduced costs and complexity could #democratize AI-driven drug discovery ▶️ We might see a renaissance in #temporal analysis of #DrugCellInteractions 🔧 For those looking to embrace this shift, check out Revvity's cutting-edge #HighContentScreening instruments (https://lnkd.in/dQFZsnAj). Their systems are well-positioned to support this new era of dynamic cellular analysis. 🤔 Thoughts? How do you see this impacting the future of drug discovery? #BiotechInnovation #DrugDiscovery #ArtificialIntelligence #PharmaTech #Innovation #CellBiology #HighContentScreening Revvity